BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) released its earnings results on Monday. BridgeBio Pharma has a 12 month low of $46.28 and a 12 month high of $93.42. Also, Director Andrea Ellis sold 17,167 shares of BridgeBio Pharma stock in a transaction that occurred on Thursday, July 9th. Check Out Our Latest Analysis on BridgeBio PharmaBridgeBio Pharma Company Profile(Get Free Report)BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. See AlsoReceive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.